The Patient Who Got a Clean Bill of Health — Twice
55-Year-Old Male · Hypertension · Type 2 Diabetes · Multi-Vessel CAD
He had seen a cardiologist. He had the tests: nuclear stress test, echocardiogram, cardiac heart monitor. All came back normal. His cardiologist told him to follow up as needed. He came to Pulse Perfect for a second opinion. The Coronary CTA and HeartFlow FFRCT revealed multi-vessel coronary artery disease, with one artery narrowed 50–60% and another blocked 50%, that the standard workup had missed entirely.
Nuclear stress tests, echocardiograms, and cardiac monitors detect ischemia and dysfunction. They do not detect plaque. A patient can have significant multi-vessel CAD and pass every one of these tests with flying colors.
What Did Traditional Medicine Say?
Traditional Cardiology
- Nuclear stress test → NORMAL
- Echocardiogram → NORMAL
- Cardiac heart monitor → NORMAL
- Standard lipid panel: LDL 117, total cholesterol 203 → 'managed'
- Conclusion: No intervention needed, follow up as needed
- No further imaging ordered — follow up 'as needed'
Pulse Perfect Approach
- Nuclear stress tests detect ischemia, not plaque — plaque can be significant without yet limiting flow
- Coronary CTA revealed CAC 162 and multi-vessel mixed plaque including 50–60% RCA stenosis
- FFRCT confirmed the 50–60% stenosis was hemodynamically non-significant — avoiding unnecessary stenting
- NMR LipoProfile: LDL-P 1,900 nmol/L, LP-IR Score 49 — metabolic syndrome actively driving plaque
- Optimal medical therapy initiated: high-intensity statin + GLP-1 agonist + structured exercise protocol
Coronary CTA with HeartFlow Analysis + FFRCT
| Vessel | Finding | % Stenosis | FFRCT | Decision |
|---|---|---|---|---|
| Proximal RCA | Predominantly calcified plaque | 25–30% | Not significant | Medical management |
| Mid RCA | Non-calcified plaque | 50–60% | Not significant hemodynamically | Medical management — avoids unnecessary stenting |
| Proximal–Mid LAD | Mixed calcified + non-calcified | 30% | N/A | Medical management |
| 2nd Diagonal Branch | Plaque | 50% | N/A | Medical Management |
| CAC Score | 162 | — | — | Establishes ASCVD — aggressive targets initiated |
Advanced Lipid & Meta
| Marker | Result | Goal | Comment |
|---|---|---|---|
| LDL Particle Number (LDL-P) | 1,900 nmol/L | < 1,000 | Severely elevated atherogenic particle burden |
| LP-IR Score | 49 | < 45 | Insulin resistance — metabolic syndrome driver |
| Fasting Glucose | 111 mg/dL | < 100 mg/dL | Elevated — pre-diabetic range |
| ApoB | Elevated | < 60 mg/dL | Goal set after ASCVD diagnosis confirmed |
| Lp(a) | 15.8 nmol/L | < 75 nmol/L | Normal — genetic risk factor absent here |
VO₂ Max, Body Composition & Epigenetics
| Metric | Value | Comment |
|---|---|---|
| VO₂ Max | 30 mL/kg/min | 25–50th percentile — average, with significant room for improvement |
| Body Fat % | 35.6% | Elevated — driving insulin resistance and atherogenesis |
| VAT (Visceral Fat) | 2.97 lbs / 87.2 in³ | Significantly elevated — priority target for reduction |
| Android/Gynoid Ratio | 1.06 | Central adiposity pattern — cardiometabolic risk |
| RMR | 2,294 kcal/day | Reasonable — supports structured caloric intervention |
Epigenetic Profile (TruAge)
| Metric | Value | Comment |
|---|---|---|
| OMICm Age (Biologic) | 55.3 yrs | Slight parity with chronologic age — minimal reserve |
| Symphony Age | 54.2 yrs | Favorable systemic aging pattern |
| Pace of Aging | 1.11× | Aging 11% faster than ideal — reversible with intervention |
| Hormone System Age | 61.2 yrs | Elevated — directly linked to insulin resistance |
| Immune System Age | 49.0 yrs | Resilient immune phenotype — a meaningful asset |
Treatment Initiated
High-intensity statin therapy targeting ApoB < 60 mg/dL and LDL < 55 mg/dL.
A GLP-1 receptor agonist was initiated for cardiovascular risk reduction and metabolic optimization, not simply weight management.
A structured Zone 2 training protocol was prescribed to improve VO₂ max and mitochondrial efficiency, with resistance training added to improve body composition and insulin sensitivity.
The Pulse Perfect 360 Blueprint delivered a full personalized cardiovascular and metabolic optimization plan with 90-day phased targets.
Key Clinical Teaching Point
What this case teaches us
- Nuclear stress tests, echocardiograms, and cardiac monitors can all be completely normal in the presence of significant multi-vessel coronary artery disease. These tests detect ischemia and dysfunction, they do not visualize plaque.
- FFRCT is a powerful and sophisticated decision-making tool: anatomic stenosis of 50–60% does not automatically equal physiologic significance. In this case, it prevented an unnecessary revascularization procedure while still mandating aggressive medical management.
- • A CAC score of 162 confirms established atherosclerosis requiring secondary prevention targets — ApoB < 60 mg/dL, LDL < 55 mg/dL, regardless of functional test results.
- An LDL particle count of 1,900 nmol/L with an LP-IR Score of 49 and fasting glucose of 111 mg/dL represents metabolic syndrome as an active atherogenesis engine. Treating the lipid number alone without addressing insulin resistance is incomplete management.
- The combination of statin + GLP-1 receptor agonist directly addresses both the lipid-driven and metabolic/inflammatory drivers of plaque simultaneously. Tthis is precision-targeted secondary prevention.
- VO₂ max of 30 mL/kg/min with 35.6% body fat, both correctable with structured intervention — improves long-term prognosis beyond what medication alone can achieve.